A Green Stability Indicating Method for Quantification of Meloxicam Using Quality by Design Principles
DOI:
https://doi.org/10.22159/ijap.2026v18i5.58870Keywords:
Meloxicam, Stability-indicating HPLC, analytical quality by design , Box-behnken Design, ValidationAbstract
Objective: To develop and validate an analytical quality by design (AQbD)guided stability indicating high-performance liquid chromatography (HPLC) method for the estimation of meloxicam in bulk drug and tablet formulations.
Methods: A systematic AQbD approach was employed using Box–Behnken Design (BBD) to evaluate the influence critical method parameters (CMP) on critical analytical attributes (CAA). Chromatographic separation was achieved on a C18 column using a mobile phase consisting of acetonitrile (ACN) and 0.1% orthophosphoric acid (75:25 % v/v). The flow rate was 1.0 mL/min with a column temperature of 45°C, and detection was performed at 364 nm. The stability-indicating capability of the method was assessed through forced degradation studies. The developed method was validated as per ICH Q2(R1) guidelines.
Results: Meloxicam was well resolved from its degradation products with a retention time of 3.63 min. The method exhibited good linearity in the concentration range of 2-18 µg/mL with a correlation coefficient (r²) of 0.9975. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.14 µg/mL and 0.45 µg/mL, respectively, indicating good sensitivity. The method demonstrated satisfactory accuracy with percentage recovery of 98.3% to 100.6% and high precision with %RSD < 2%. The developed method was successfully applied to the assay of meloxicam in tablet formulations, confirming its suitability for routine analysis. The greenness of the method was also evaluated using the AGREE tool.
Conclusion: The developed AQbD-based stability-indicating HPLC method is robust, accurate, precise, and environmentally acceptable. The method is suitable for routine quality control and stability analysis of meloxicam in bulk and pharmaceutical dosage forms.
References
1. Ma L, Cranney A, Holroyd-Leduc JM. Acute monoarthritic: what is the cause of my patient’s painful swollen joint? Canadian Medical Association Journal. 2009 Jan 6;180(1):59–65. doi:10.1503/CMAJ.080183. PubMed PMID: 19124791.
2. Lorig K, Konkol L, Gonzalez V. Arthritis patient education: a review of the literature. Patient Educ Couns. 1987 Dec;10(3):207-52. doi:10.1016/0738-3991(87)90126-1. PMID: 10302113.
3. Garino JP, Beredjiklian PK. Core Knowledge in Orthopaedics: Adult Reconstruction and Arthroplasty. 1st ed. St. Louis (MO): Mosby; 2007.
4. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem. 2012;11(1):52-64. doi:10.2174/187152312803476255. PMID: 22934743.
5. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med. 1991 Jun 13;324(24):1716-25. doi:10.1056/NEJM199106133242407. Erratum in: N Engl J Med 1991 Sep 5;325(10):747. PMID: 2034249.
6. Mucklow JC. Martindale: The Complete Drug Reference. Br J Clin Pharmacol. 2000 Jun;49(6):613. doi:10.1046/j.1365-2125.2000.00206.x.
7. Khalil NY, Aldosari KF. Meloxicam. Profiles Drug Subst Excip Relat Methodol. 2020;45:159-197. doi:10.1016/bs.podrm.2019.10.006. Epub 2019 Dec 12. PMID: 32164967.
8. Bekker A, Kloepping C, Collingwood S. Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi:10.4103/joacp.JOACP_133_18. PMID: 30774225; PMCID: PMC6360894.
9. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug: a review. Clin Drug Investig. 2002;22(12):799-818. doi:10.2165/00044011-200222120-00001.
10. Schattenkirchner M. Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert Opin Investig Drugs. 1997 Mar;6(3):321-34. doi:10.1517/13543784.6.3.321. PMID: 15989631.
11. Arayne MS, Sultana N, Siddiqui FA. A new reverse phase high performance liquid chromatographic method for analysis of meloxicam in tablets. Pak J Pharm Sci. 2005 Jan;18(1):58-62.
12. Sinha PK, Jeswani RM, Topagi KS, Damle MC. A validated RP-HPLC method for determination of meloxicam in the presence of its impurities. Int J PharmTech Res. 2009;1(4):1051-1060.
13. Bandarkar FS, Vavia PR. A stability-indicating HPLC method for the determination of meloxicam in bulk and commercial formulations. Trop J Pharm Res. 2009;8(3):257-264. doi:10.4314/tjpr.v8i3.44543.
14. Hassan EM. Spectrophotometric and fluorimetric methods for the determination of meloxicam in dosage forms. J Pharm Biomed Anal. 2002 Feb 1;27(5):771-7. doi:10.1016/s0731-7085(01)00530-1. PMID: 11814718.
15. Sahoo NK, Sahu M, Rao PS, Rani NS, Devi JN, Ghosh G. Validation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC. SpringerPlus. 2014;3:95. doi:10.1186/2193-1801-3-95. PMID:24711980; PMCID:PMC3977022.
16. Dhandapani B, Eswara Murali S, Susrutha N, Swetha R, Rani SK, Sarath Babu T, Seetharamanjaneyulu, Baboo R.V.C. Spectrophotometric estimation of meloxicam in bulk and its pharmaceutical formulations. Int J Pharm Sci Res. 2010;1(4):217-221.
17. Aydoğmuş Z, Alim F. Determination of meloxicam in tablets by third derivative UV spectrophotometric method. J Adv Res Health Sci. 2024;7(1):61-67. doi:10.26650/JARHS2024-1238611.
18. Desai N, Amin P. Stability Indicating HPTLC Determination of Meloxicam. Indian J Pharm Sci. 2008 Sep;70(5):644-7. doi:10.4103/0250-474X.45406. PMID: 21394264; PMCID: PMC3038292.
19. Ganesh M, Hemalatha P, Peng MM, Sakthimanigandan K, Jang HT. Estimation of meloxicam in human plasma by liquid chromatography–tandem mass spectrometry (LC-MS/MS). J Liq Chromatogr Relat Technol. 2013;36(7):867-880. doi:10.1080/10826076.2012.678453.
20. Wiesner JL, de Jager AD, Sutherland FC, Hundt HK, Swart KJ, Hundt AF, Els J. Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of meloxicam in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 25;785(1):115-21. doi: 10.1016/s1570-0232(02)00862-0. PMID: 12535844.
21. Jyothi VGSS, Veerabomma H, Katta C, Madan J. Computational quality-by-design strategy to validate high-performance liquid chromatography method for the estimation of meloxicam in bulk dosage forms and milk samples. Anal Sci. 2024 Feb;40(2):249-261. doi: 10.1007/s44211-023-00448-9. Epub 2023 Oct 26. PMID: 37882956.
22. Puranpole AA, Chavan VA, Kodrikar P, Mali G. Analytical quality by design (QbD) approach to RP-HPLC method development and validation of meloxicam. Asian J Pharm Technol Innov. 2016;4(20):1-10.
23. Seles KS, Padmavathi S, Abdul Rahaman S, Shabana Azmi SK, Shiny Grace D, Amreen Sahana M. Development and validation of stability-indicating assay for simultaneous determination of bupivacaine and meloxicam in bulk and pharmaceutical formulations by using RP-HPLC method. Int J Life Sci Pharma Res. 2022;12(6):117-131. doi:10.22376/ijpbs/lpr.2022.12.6.
24. Zaman M, Hanif M, Khan NUH, Mahmood A, Qaisar MN, Ali H. Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of tizanidine HCl and meloxicam in rabbit’s plasma. Acta Chromatogr. 2019;31(3):173-178. doi:10.1556/1326.2018.00408.
25. Bahgat EA, Hashem H, Saleh H, Kamel EB, Eissa MS. Stability-indicating HPLC-DAD and TLC-densitometry methods for the quantification of bupivacaine and meloxicam in their co-formulated mixture. Microchem J. 2023;190:108683. doi:10.1016/j.microc.2023.108683.
26. Chatterjee S. QbD considerations for analytical methods: FDA perspective. Presented at: IFPAC Annual Meeting; 2013 Jan 25; Baltimore, MD, USA. Available from: http://qbdworks.com/wp-content/uploads/2014/06/AnalyticalQbDIFPAC.pdf
27. International Council for Harmonisation. ICH Q8(R2). Pharmaceutical Development. Geneva: ICH; 2009.
28. Ganorkar AV, Gupta KR. Analytical quality by design: a mini review. Biomed J Sci Tech Res. 2017;1(6):1555-1559. doi:10.26717/BJSTR.2017.01.000484.
29. Kumar N, Fathima ARS, Sangeetha K, Karthika R, Alfi R, Jose E. A mini overview of analytical quality by design (AQbD). Int J Pharm Sci. 2026;4(2):792-8. doi: 10.5281/zenodo.18493651.
30. Stojanović J, Krmar J, Protić A, Svrkota B, Đajić N, Otašević B. DoE experimental design in HPLC separation of pharmaceuticals: a review. Arh Farm (Belgr). 2021;71(4):279-301. doi:10.5937/arhfarm71-32480.
31. Bhutani H, Kurmi M, Singh S, Beg S, Singh B. Quality by design (QbD) in analytical sciences: an overview. Quality Assurance 2004;3:39-45.
32. International Council for Harmonisation. ICH Q1A(R2). Stability testing of new drug substances and products. Geneva: ICH; 2003.
33. Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, Li Y, Marden S, Mohan S, Ultramari M, Huang Z, Adams N, Campbell JM, Jansen PJ, Kotoni D, Laue C. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. J Pharm Sci. 2023 Dec;112(12):2948-2964. doi:10.1016/j.xphs.2023.09.003. Epub 2023 Sep 9. PMID: 37690775.
34. Yulianita R, Sopyan I, Muchtaridi M. Forced degradation study of statins: a review. Int J Appl Pharm. 2018 Nov-Dec;10(6):38-42. doi:10.22159/ijap.2018v10i6.29086.
35. Bairagi A, Kothrukar R, Chikhale H, Kosanam S, Borse L. AQbD-novel strategy for analytical methods. Future J Pharm Sci. 2024;10:138. doi:10.1186/s43094-024-00706-1.
36. Rozet E, Lebrun P, Debrus B, Boulanger B, Hubert P. Design spaces for analytical methods. TrAC Trends Anal Chem. 2013;42:157-167. doi:10.1016/j.trac.2012.09.007.
37. Beg S, Hasnain MS, Rahman M, editors. Introduction to quality by design (QbD): fundamentals, principles, and applications. In: Pharmaceutical quality by design: principles and applications. London: Academic Press; 2019. p. 1-17. doi:10.1016/B978-0-12-815799-2.00001-0.
38. International Council for Harmonisation. ICH Q9. Quality risk management. Geneva: ICH; 2005
39. Pande PP, Sayyad SF, Chavan MJ, Chaudhari SR. Quality by design in analytical method development and validation. J Environ Life Sci. 2017 Jun;2(2):39-45.
40. Peraman R, Bhadraya K, Padmanabha Reddy Y. Analytical quality by design: a tool for regulatory flexibility and robust analytics. Int J Anal Chem. 2015;2015:868727. doi:10.1155/2015/868727. Epub 2015 Feb 2. PMID: 25722723; PMCID: PMC4332986.
41. International Council for Harmonisation. ICH Q10. Pharmaceutical quality system. Geneva: ICH; 2008
42. Deidda R, Orlandini S, Hubert P, Furlanetto S. Risk-based approach for method development in pharmaceutical quality control context: a critical review. J Pharm Biomed Anal. 2018 Nov 30;161:110-121. doi:10.1016/j.jpba.2018.07.050.
43. Orlandini S, Pinzauti S, Furlanetto S. Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem. 2013 Jan;405(2-3):443-50. doi:10.1007/s00216-012-6302-2. Epub 2012 Sep 2. PMID: 22941176.
44. International Council for Harmonisation. ICH Q2 (R1). Validation of analytical procedures: text and methodology. Geneva: ICH; 2014
45. Patel S, Ty P. Stability-indicating high-performance liquid chromatography method for determination of antihistamine drug azelastine. Asian J Pharm Clin Res. 2018 Aug;11(8):248-251. doi:10.22159/ajpcr.2018.v11i8.25506.
46. Patel MN, Nandpal MN, Patel AJ, Raval MA, Patel SG. Development and Validation of a Green Stability-Indicating HPTLC Method for Estimation of Curcumin, Gallic Acid, and Ursolic Acid from Polyherbal Formulation Jatyadi Taila. J AOAC Int. 2023 Jul 17;106(4):979-991. doi:10.1093/jaoacint/qsac147. PMID: 36440895.
47. Zawilla NH, Abdul-Azim Mohammad M, El kousy NM, El-Moghazy Aly SM. Determination of meloxicam in bulk and pharmaceutical formulations. J Pharm Biomed Anal. 2003 Aug 21;32(6):1135-44. doi:10.1016/s0731-7085(03)00232-2. PMID: 12907256.
48. Bartos D, Szabó Z, Németh G, Klebovich I. Photostability of meloxicam in solution and in solid state. J Pharm Biomed Anal. 2005;39(3-4):817-820. doi:10.1016/j.jpba.2005.04.012.
Published
How to Cite
Issue
Section
Copyright (c) 2026 LILADHAR MARATHE, SHITAL PATEL, MINAL SALUNKHE; ARCHITA PATEL; MEGHANA PATEL
This work is licensed under a Creative Commons Attribution 4.0 International License.